A recent article in the Financial Times examined the enduring challenges surrounding antibiotic development and whether recent advances in artificial intelligence may help yield new therapies.
But for all the optimism, Henry Skinner, chief executive of the AMR Action Fund, says AI is “helpful, certainly, but not transformative” because it does little to address where the real costs lie: in clinical trials. He thinks even his fund is “at best, a stop gap, partial solution”. “We feel a huge amount of responsibility. One billion dollars sounds like a lot of money but it is not nearly enough for the very expensive last-stage work,” he says.
Read the article in full at the Financial Times.
